Filing Details
- Accession Number:
- 0001104659-22-004515
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-14 18:14:00
- Reporting Period:
- 2022-01-03
- Accepted Time:
- 2022-01-14 18:14:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1640266 | Voyager Therapeutics Inc. | VYGR | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1894915 | Julie Burek | C/O Voyager Therapeutics, Inc., 75 Sidney Street Cambridge MA 02139 | Vp, Finance | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-12-31 | 3,063 | $2.30 | 49,585 | No | 5 | A | Direct | |
| Common Stock | Disposition | 2022-01-03 | 3,063 | $2.83 | 46,522 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-01-12 | 265 | $3.06 | 46,257 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 5 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Represents shares acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
- Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.92 to $3.22, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Billionaire Hedge Funds
